MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$10,580,000
EPS
-$0.26
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenue-License
-
-
-
0
Total revenue
-
0
0*
0
Total revenue-License
-
0
-
-
Impairment of long-lived assets
-
0
-9,334,000*
4,667,000
Research and development
3,923,000
3,593,000
5,549,500*
5,390,000
Goodwill impairment
-
-
0*
-
General and administrative
7,101,000
2,528,000
17,007,000*
5,165,000
Total operating expenses
11,024,000
6,121,000
13,222,500*
15,222,000
Other operating income
5,000
46,000
252,500*
156,000
Loss from operations
-11,019,000
-6,075,000
-12,970,000*
-15,066,000
Interest income
343,000
350,000
464,500*
472,000
Interest expense
14,000
13,000
13,500*
13,000
Research and development incentives
42,000
149,000
-373,000*
240,000
Other income
26,000
39,000
-51,500*
-275,000
Total other income, net
397,000
525,000
26,500*
424,000
Loss before income tax
-10,622,000
-5,550,000
-12,943,500*
-14,642,000
Tax benefit
-23,000
-16,000
-31,000*
-71,000
Net loss
-10,599,000
-5,534,000
-12,912,500*
-14,571,000
Net loss attributable to noncontrolling interest
-19,000
-3,000
-19,500*
-5,000
Net loss attributable to barinthus biotherapeutics plc shareholders
-10,580,000
-5,531,000
-12,893,000
-14,566,000
Basic EPS
-0.26
-0.14
-0.318
-0.36
Diluted EPS
-0.26
-0.14
-0.318
-0.36
Basic Average Shares
40,848,893
40,848,893
40,577,015
40,661,118
Diluted Average Shares
40,848,893
40,848,893
40,577,015
40,661,118
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
attributable to barinthus...
-$10,580,000
(49.91%↑ Y/Y)
Net loss
attributable to...
-$19,000
(-850.00%↓ Y/Y)
Net loss
-$10,599,000
(49.83%↑ Y/Y)
Tax benefit
-$23,000
(8.00%↑ Y/Y)
Interest income
$343,000
(-34.42%↓ Y/Y)
Research and development
incentives
$42,000
(-96.87%↓ Y/Y)
Other income
$26,000
(-91.88%↓ Y/Y)
Loss before income
tax
-$10,622,000
(49.78%↑ Y/Y)
Total other income,
net
$397,000
(-81.73%↓ Y/Y)
Interest expense
$14,000
(16.67%↑ Y/Y)
Loss from operations
-$11,019,000
(52.76%↑ Y/Y)
Other operating
income
$5,000
(-61.54%↓ Y/Y)
Total operating
expenses
$11,024,000
(-52.76%↓ Y/Y)
General and
administrative
$7,101,000
(-53.84%↓ Y/Y)
Research and development
$3,923,000
(-50.67%↓ Y/Y)
Buy us a coffee
Barinthus Biotherapeutics plc. (BRNS)
Barinthus Biotherapeutics plc. (BRNS)